康拓医疗(688314) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥64,642,702.97, representing a year-on-year increase of 20.82%[5] - The net profit attributable to shareholders for the same period was ¥19,419,917.13, reflecting a growth of 7.70% compared to the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.33, showing an increase of 6.45% from the same period last year[6] - The net profit for Q1 2023 was CNY 19,079,127.44, representing an increase of 8.5% compared to CNY 17,578,386.38 in Q1 2022[18] - Total revenue from operating activities reached CNY 78,281,483.00, up from CNY 58,527,987.95 in the same period last year, indicating a growth of 33.7%[21] - The total comprehensive income for the period was CNY 18,884,533.92, compared to CNY 17,491,604.14 in the same quarter last year, showing an increase of 8.0%[19] Research and Development - Research and development expenses totaled ¥4,000,571.62, which is an increase of 61.23% year-on-year, indicating a significant investment in innovation[6] - Research and development expenses increased to CNY 4,000,571.62, compared to CNY 2,481,241.25 in the previous year, reflecting a growth of 61.4%[18] Cash Flow and Assets - The net cash flow from operating activities was ¥13,837,410.61, which represents a decline of 11.62% year-on-year[5] - Cash and cash equivalents decreased to RMB 255,710,751.50 as of March 31, 2023, down from RMB 349,241,669.41 at the end of 2022, a decline of 26.7%[14] - The company reported a net cash flow from operating activities of CNY 13,837,410.61, a decrease from CNY 15,656,175.96 in Q1 2022[22] - The company incurred a net cash outflow from investing activities of CNY -108,821,161.64, an improvement from CNY -170,936,303.22 in the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥645,679,581.22, an increase of 1.18% from the end of the previous year[6] - The total assets as of March 31, 2023, were RMB 645,679,581.22, compared to RMB 638,135,743.88 at the end of 2022, showing a slight increase of 1.1%[16] - The total liabilities decreased to RMB 85,113,166.39 as of March 31, 2023, from RMB 96,462,236.78 at the end of 2022, a reduction of 11.4%[16] - The equity attributable to shareholders increased to RMB 562,507,080.16 as of March 31, 2023, compared to RMB 543,283,167.02 at the end of 2022, an increase of 3.5%[16] Shareholder Information - The company had a total of 3,366 common shareholders at the end of the reporting period[10] - The largest shareholder, Hu Liren, holds 48.54% of the shares, amounting to 28,168,420 shares[10] Operational Efficiency - The total operating costs for Q1 2023 amounted to RMB 41,550,307.81, up from RMB 31,854,707.27 in Q1 2022, reflecting a growth of 30.5%[17] - The company reported a net profit margin improvement due to increased revenue and controlled costs, although specific profit figures were not disclosed in the provided content[17] - Sales and service cash receipts totaled CNY 75,942,249.47, up from CNY 57,473,707.41 in Q1 2022, marking a growth of 32.3%[20] Strategic Focus - The company is focusing on expanding its market presence and enhancing product development, although specific new products or technologies were not detailed in the provided content[17] - The company continues to focus on enhancing its financial position through strategic asset management and investment in growth opportunities[24]